WASHINGTON: Responding to an outcry from medical experts, Food and Drug Administration Commissioner Stephen Hahn on Tuesday apologized for overstating the life-saving benefits of treating COVID-19 patients with convalescent plasma.
Scientists and medical experts have been pushing back against the claims about the treatment since President Donald Trumps announcement on Sunday that the FDA had decided to issue emergency authorization for convalescent plasma, taken from patients who have recovered from the coronavirus and rich in antibodies.
Trump hailed the decision as a historic breakthrough even though the treatments value has not been established. The announcement on the eve of Trumps Republican National Convention raised suspicions that it was politically motivated to offset critics of the president’s handling of the pandemic.
Hahn had echoed Trump in saying that 35 more people out of 100 would survive the coronavirus if they were treated with the plasma. That claim vastly overstated preliminary findings of Mayo Clinic observation.
The 35% figure drew condemnation from other scientists and some former FDA officials, who called on Hahn to correct the record.
I have been criticized for remarks I made Sunday night about the benefits of convalescent plasma. The criticism is entirely justified. What I should have said better is that the data show a relative risk reduction not an absolute risk reduction, Hahn tweeted.
The FDA made the decision based on data the Mayo Clinic collected from hospitals around the country that were using plasma on patients in wildly varying ways — and there was no comparison group of untreated patients, meaning no conclusions can be drawn about overall survival. People who received plasma with the highest levels of antibodies fared better than those given plasma with fewer antibodies, and those treated sooner after diagnosis fared better than those treated later.
Its extraordinary to me that a person involved in clinical trials could make that mistake, said Dr. Peter Lurie, a former FDA official under the Obama administration who now leads the nonprofit Center for Science in the Public Interest. Its mind-boggling.
Hahn has been working to bolster confidence in the agencys scientific process, stating in interviews and articles that the FDA will not approve any vaccine that doesnt meet preset standards for safety and efficacy.
Lurie said Hahns performance at the press conference undermined his credibility, particularly among FDA staff.
I think within the agency his credibility is massively reduced as a result, Lurie said.
On Monday, House Speaker Nancy Pelosi, a Democrat, called Hahn a disappointment and said House committees were looking into FDA actions.
Trump has recently accused some FDA staff, without evidence, of deliberately holding up new treatments for political reasons. And Trumps chief of staff, Mark Meadows, said over the weekend that FDA scientists need to feel the heat.”
The administration has sunk vast resources into the race for a vaccine, and Trump aides have been hoping that swift progress could help the president ahead of Novembers election.
At Sundays briefing Hahn did not correct Trumps description of the regulatory move as a breakthrough. He also did not contradict Trumps unsupported claim of a deep state effort at the agency working to slow down approvals.
Former FDA officials said the political pressure and attacks against the FDA carry enormous risk of undermining trust in the agency just when its needed most. A vaccine will only be effective against the virus if it is widely taken by the U.S. population.
I think the constant pressure, the name-calling, the perception that decisions are made under pressure is damaging, said Dr. Jesse Goodman of Georgetown University, who previously served as FDAs chief scientist. We need the American people to have full confidence that medicines and vaccines are safe,
Convalescent plasma is a century-old approach to treating the flu, measles and other viruses. But the evidence so far has not been conclusive about whether it works, when to administer it and what dose is needed.
The FDA emergency authorization is expected to increase its availability to additional hospitals. But more than 70,000 Americans have already received the therapy under FDAs expanded access program. That program tracks patients’ response, but cannot prove whether the plasma played a role in their recovery.
Some scientists worry the broadened FDA access to the treatment will make it harder to complete studies of whether the treatment actually works. Those studies require randomizing patients to either receive plasma or a dummy infusion.
___
Associated Press writer Lauran Neergaard contributed to this report.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor
Comments
0 comment